The recent study on twice-yearly shots for AIDS treatment has shown impressive results, particularly in preventing new HIV infections among women.

The research involved around 5,000 participants in South Africa and Uganda, demonstrating 100% effectiveness in those receiving the shots compared to a 2% infection rate among those using daily prevention pills.

This breakthrough has been hailed as “stunning” by experts like Salim Abdool Karim for its potential impact on HIV prevention efforts, especially in regions where consistent pill usage has been a challenge.

Gilead’s lenacapavir injections, currently approved for HIV treatment, may soon be sought for preventative use pending further testing in men.

This development could offer a revolutionary alternative to daily pills, addressing stigma and enhancing options for HIV prevention.